Aerie Pharmaceuticals, Inc. (AERI) Position Boosted by Rhumbline Advisers

Rhumbline Advisers boosted its position in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 3.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 34,913 shares of the company’s stock after buying an additional 1,237 shares during the period. Rhumbline Advisers owned approximately 0.10% of Aerie Pharmaceuticals worth $1,835,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Rice Hall James & Associates LLC lifted its holdings in Aerie Pharmaceuticals by 23.4% in the second quarter. Rice Hall James & Associates LLC now owns 244,795 shares of the company’s stock valued at $12,864,000 after buying an additional 46,482 shares during the period. C WorldWide Group Holding A S lifted its holdings in Aerie Pharmaceuticals by 17.7% in the second quarter. C WorldWide Group Holding A S now owns 89,549 shares of the company’s stock valued at $4,706,000 after buying an additional 13,458 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in Aerie Pharmaceuticals by 1.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 138,289 shares of the company’s stock valued at $7,268,000 after buying an additional 2,183 shares during the period. Trexquant Investment LP acquired a new position in Aerie Pharmaceuticals in the second quarter valued at $405,000. Finally, Palisade Capital Management LLC NJ acquired a new position in Aerie Pharmaceuticals in the second quarter valued at $212,000. Institutional investors and hedge funds own 94.64% of the company’s stock.

Several research firms recently issued reports on AERI. Mizuho began coverage on shares of Aerie Pharmaceuticals in a report on Wednesday, September 6th. They issued a “buy” rating and a $70.00 target price on the stock. Zacks Investment Research lowered shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 28th. Canaccord Genuity set a $65.00 target price on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 16th. HC Wainwright set a $69.00 target price on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 2nd. Finally, Stifel Nicolaus restated a “buy” rating and issued a $70.00 target price on shares of Aerie Pharmaceuticals in a report on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $66.36.

ILLEGAL ACTIVITY NOTICE: “Aerie Pharmaceuticals, Inc. (AERI) Position Boosted by Rhumbline Advisers” was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://transcriptdaily.com/2017/09/17/aerie-pharmaceuticals-inc-aeri-position-boosted-by-rhumbline-advisers.html.

Aerie Pharmaceuticals, Inc. (NASDAQ AERI) opened at 58.30 on Friday. The firm’s market cap is $2.12 billion. The stock’s 50 day moving average is $54.57 and its 200 day moving average is $49.84. Aerie Pharmaceuticals, Inc. has a one year low of $32.05 and a one year high of $60.15.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.02. On average, analysts predict that Aerie Pharmaceuticals, Inc. will post ($2.59) earnings per share for the current fiscal year.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply